Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (389 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-12-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subject hasthe subjectsubject ishypertensionpulmonary
  Phrases that lowered it: and safetyto evaluatesafety offev1period
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 16.4% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Keywords listed: 21 (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 64.3% (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Design: sequential (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Blinding: none (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 8382 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy NCT01560624 · started 2012 · scored riskier than 94% of active trials completed
• A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients NCT03626688 · started 2019 · scored riskier than 88% of active trials completed
• A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH) NCT03177603 · started 2018 · scored riskier than 39% of active trials completed
• Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil NCT03399604 · started 2018 · scored riskier than 55% of active trials completed
• Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH NCT02725372 · started 2016 · scored riskier than 97% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.